FDA Grants Orphan Drug Designation to Cardiol Therapeutics' Lead Candidate for Recurrent Pericarditis| David Elsley, CEO, Cardiol Therapeutics Inc. 00:10:00
Cardiol Therapeutics CEO David Elsley discusses the FDA's recent grant of Orphan Drug Designation for the company's lead small molecule drug candidate targeting pericarditis, emphasizing its potential to improve patients' quality of life. This milestone underscores the significance of CardiolRx in addressing a debilitating heart condition and highlights the company's commitment to advancing innovative therapies for cardiovascular diseases.